证券代码：600165 股票简称：*ST 宁科 公告编号：临 2024-052 宁夏中科生物科技股份有限公司 关于聘请离任审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 成立日期：2022 年 3 月 17 日 宁夏中科生物科技股份有限公司（以下简称：公司）第九届董事会第二十四 次会议审议通过了《关于公司开展离任审计的议案》，公司拟聘请具有执行证券 相关业务资格的会计师事务所进行离任审计。2024 年 4 月 30 日，公司召开第九 届董事会审计委员会 2024 年第一次会议，审议通过了《关于聘请离任审计机构 的议案》，同意聘请江苏苏港会计师事务所（特殊普通合伙）担任公司本次离任 审计的审计机构。 一、离任审计的目的 公司开展本次离任审计的目的，是为了查明在过往经营活动中，高级管理人 员或者公司董事，是否存在包括但不限于渎职、经营决策错误、损害公司业务发 展、利用公司违规获利等情形，致使公司主营业务陷入停顿，近三年净利润为负 值，并被实施风险警示。 二、聘请离任审计机构的基本情况 （一）机构信息 1、基本信息 ...

重要内容提示： ● 上海中能企业发展（集团）有限公司（以下简称：上海中能）持有宁夏 中科生物科技股份有限公司（以下简称：公司）股份数量 20,000 万股，占公司 总股本的 29.20%。 ● 上海中能持有公司股份数量 20,000 万股被广东省广州市中级人民法院 司法冻结，本次被冻结的股份占其持股总数的 100%，占公司总股本的 29.20%。 ● 截至本公告披露日，上海中能持有公司股份累计冻结数量 20,000 万股， 占其持股总数的 100%，占公司总股本的 29.20%。 证券代码：600165 股票简称：*ST 宁科 公告编号：临 2024-051 宁夏中科生物科技股份有限公司 关于控股股东股份冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2024 年 4 月 29 日收到公司控股股东上海中能通知，获悉其收到中国 证券登记结算有限责任公司上海分公司《股权司法冻结及司法划转通知》，广东 省广州市中级人民法院就广州农村商业银行股份有限公司与上海中能、武汉晨鸣 万兴置业有限公司、虞建明金融借款合同纠纷 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥53,896,659.24, representing a year-on-year increase of 16.89%[5] - The net profit attributable to shareholders was -¥51,454,550.60, indicating a significant loss[5] - The net cash flow from operating activities was -¥333,734.47, reflecting challenges in cash generation[5] - The weighted average return on net assets was -36.202%, highlighting the impact of the net profit decline[5] - The company reported a basic and diluted earnings per share of -¥0.075 for the quarter[5] - The net loss attributable to the parent company for Q1 2024 was CNY -1,046,177,792.36, worsening from CNY -994,723,241.77 in Q4 2023[22] - The net profit for Q1 2024 was -57,972,305.47 RMB, an improvement from -66,686,256.61 RMB in Q1 2023, representing a decrease in net loss of approximately 13%[24] - Operating profit for Q1 2024 was -53,772,402.75 RMB, compared to -66,667,320.60 RMB in the same period last year, indicating a reduction in operating loss of about 19%[24] - The total comprehensive income for Q1 2024 was -58,117,992.78 RMB, an improvement from -66,412,010.82 RMB in Q1 2023, indicating a reduction in comprehensive loss of about 12%[24] - Basic and diluted earnings per share for Q1 2024 were both -0.075 RMB, compared to -0.085 RMB in Q1 2023, showing an improvement in earnings per share[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,935,317,213.80, a decrease of 0.75% compared to the end of the previous year[5] - Shareholders' equity attributable to the company decreased by 30.74% to ¥116,259,504.86, primarily due to reduced net profit[5] - Total current assets as of March 31, 2024, amounted to CNY 202,100,530.36, slightly up from CNY 198,695,245.81 at the end of 2023[20] - Total liabilities as of March 31, 2024, were CNY 2,611,444,306.71, an increase from CNY 2,575,523,648.67 at the end of 2023[21] - The total assets as of March 31, 2024, were CNY 2,935,317,213.80, down from CNY 2,957,514,548.54 at the end of 2023[22] - The cash and cash equivalents decreased to CNY 21,587,451.13 from CNY 24,399,349.84 at the end of 2023, reflecting a decline of 11.5%[19] - The inventory as of March 31, 2024, was CNY 112,547,273.35, an increase of 17.5% compared to CNY 95,831,731.76 at the end of 2023[20] Operational Challenges - The company has not provided guidance for future performance or new product developments in this report[5] - The company’s subsidiary, Ningxia Zhongke Biological New Materials Co., Ltd., is currently in a temporary shutdown and is expected to be unable to resume normal operations within one month[12] - The company is facing a restructuring application from creditors due to inability to repay debts and is contesting this application in court[15] - The company is currently organizing efforts to restart production at its subsidiary, but the timeline for full recovery remains uncertain[12] Risk Factors - The company’s stock has been placed under risk warning due to continuous negative net profits over three consecutive years from 2021 to 2023[13] - The company’s stock will be subject to delisting risk warnings starting April 30, 2024, following an audit report that expressed an inability to provide an opinion on the financial statements[16] - The company is under delisting risk warning from the Shanghai Stock Exchange effective April 30, 2024, due to financial conditions[17] - The company’s stock has been under other risk warnings since April 8, 2024, due to the subsidiary's operational issues[12] Liquidity Support - The company has signed a liquidity support agreement to provide a guarantee of RMB 60 million for the financing of its subsidiary, with RMB 20 million already received[14] - The liquidity support plan for the subsidiary has been extended until December 31, 2024, to assist in resuming production[14] Revenue and Costs - The increase in operating revenue was mainly driven by higher sales volume from Huahui Environmental Protection[8] - The total operating revenue for Q1 2024 was CNY 53,896,659.24, an increase of 16.1% compared to CNY 46,109,368.75 in Q1 2023[23] - The total operating costs for Q1 2024 were CNY 107,461,892.17, a decrease of 6.8% from CNY 115,018,464.73 in Q1 2023[23] - The operating cost specifically for Q1 2024 was CNY 55,564,166.43, down from CNY 71,983,460.43 in Q1 2023, indicating a significant reduction of 22.7%[23] Cash Flow - The net cash flow from operating activities for Q1 2024 was -333,734.47 RMB, a significant improvement from -42,832,422.48 RMB in Q1 2023[27] - The cash and cash equivalents at the end of Q1 2024 stood at 19,021,898.11 RMB, compared to 9,415,253.24 RMB at the end of Q1 2023, reflecting an increase of approximately 102%[28] - The net cash flow from investing activities for Q1 2024 was 1,772,700.25 RMB, a recovery from -804,450.00 RMB in Q1 2023[28] - The net cash flow from financing activities for Q1 2024 was -4,250,879.04 RMB, compared to 9,824,818.42 RMB in Q1 2023, indicating a shift in financing cash flow[28] - The company reported a tax expense of -137,144.96 RMB in Q1 2024, compared to -52,993.21 RMB in Q1 2023, reflecting an increase in tax-related losses[24]

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2024-049 宁夏中科生物科技股份有限公司 股票交易风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 宁夏中科生物科技股份有限公司（以下简称：公司）股票于 2024 年 4 月 26 日跌停，于 2024 年 4 月 30 日涨停，当日振幅达到 9.82%，单日换手率达到 22.83%。近期，公司股票交易价格波动幅度较大，敬请广大投资者注意二级市 场交易风险。 ● 宁夏中科生物新材料有限公司（以下简称：中科新材）目前处于临时停产 状态，根据《上海证券交易所股票上市规则》的相关规定，公司股票自 2024 年 4 月 8 日起已被上海证券交易所实施其他风险警示。截至本公告披露日，前述 "其他风险警示"情形尚未解除。 ● 因公司 2021 年至 2023 年连续三个会计年度经审计扣除非经常性损益前 后净利润孰低者均为负值，且 2023 年度审计报告显示公司持续经营能力存在不 确定性，根据《上海证券交易所股票上市规则》的相关规定，公 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥53,896,659.24, representing a year-on-year increase of 16.89%[5] - The net profit attributable to shareholders was -¥51,454,550.60, indicating a significant loss[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥44,563,280.21[5] - The net cash flow from operating activities was -¥333,734.47, reflecting cash flow challenges[5] - The weighted average return on net assets was -36.202%, indicating a decline in profitability[5] - The net loss attributable to the parent company was CNY -1,046,177,792.36, worsening from CNY -994,723,241.77 in the previous period[22] - The net profit for Q1 2024 was -57,972,305.47 RMB, an improvement from -66,686,256.61 RMB in Q1 2023, representing a decrease in net loss of approximately 13%[24] - Operating profit for Q1 2024 was -53,772,402.75 RMB, compared to -66,667,320.60 RMB in the same period last year, indicating a reduction in operating loss of about 19%[24] - Total comprehensive income for Q1 2024 was -58,117,992.78 RMB, an improvement from -66,412,010.82 RMB in Q1 2023, reflecting a decrease in total comprehensive loss of approximately 12%[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,935,317,213.80, a decrease of 0.75% from the previous year[5] - The equity attributable to shareholders decreased by 30.74% to ¥116,259,504.86 compared to the end of the previous year[5] - Total assets as of March 31, 2024, were CNY 2,935,317,213.80, slightly down from CNY 2,957,514,548.54 at the end of 2023[22] - Current assets totaled CNY 202,100,530.36, a marginal increase from CNY 198,695,245.81 in December 2023[20] - The total liabilities increased to CNY 2,611,444,306.71 from CNY 2,575,523,648.67, representing a rise of 1.4%[21] Cash Flow - Cash flow from operating activities for Q1 2024 was -333,734.47 RMB, a significant improvement from -42,832,422.48 RMB in Q1 2023[27] - Cash flow from investing activities generated a net inflow of 1,772,700.25 RMB in Q1 2024, compared to a net outflow of -804,450.00 RMB in Q1 2023[28] - Cash flow from financing activities resulted in a net outflow of -4,250,879.04 RMB in Q1 2024, contrasting with a net inflow of 9,824,818.42 RMB in Q1 2023[28] Sales and Revenue - The increase in operating revenue was primarily due to increased sales volume from Huahui Environmental Protection[8] - The total operating revenue for Q1 2024 was CNY 53,896,659.24, an increase of 16.1% compared to CNY 46,109,368.75 in Q1 2023[23] - The total operating costs decreased to CNY 107,461,892.17 in Q1 2024 from CNY 115,018,464.73 in Q1 2023, reflecting a reduction of 6.8%[23] - The operating cost of goods sold was CNY 55,564,166.43, down from CNY 71,983,460.43, indicating a decrease of 22.7%[23] - The company reported sales revenue of 51,725,699.49 RMB in Q1 2024, an increase from 43,227,729.40 RMB in Q1 2023, marking a growth of approximately 19%[27] Company Challenges - The company has signed a cooperation agreement for financial assistance with the local government, which includes a financing guarantee of RMB 60 million for its subsidiary[14] - The company’s stock has been placed under risk warning due to continuous negative net profits over the past three years, with the latest audit report indicating uncertainty in the company's ability to continue operations[13] - The company has received a notice from the court regarding a restructuring application due to its inability to repay debts, which poses significant uncertainty for its future operations[15] - The company’s stock will face delisting risk as it has been placed under additional risk warnings following an audit report that expressed an inability to provide an opinion on the financial statements[16] - The company is under delisting risk warning from the Shanghai Stock Exchange effective April 30, 2024, due to financial conditions[17] - The company experienced a significant decrease in equity due to reduced net profit attributable to shareholders[8] - The company reported a non-recurring loss of -¥2,851,235.46 from the disposal of non-current assets[7] - The company’s subsidiary, Ningxia Zhongke Biological New Materials Co., Ltd., is currently in a temporary shutdown and is expected to be unable to resume normal operations within one month[12] Shareholder Information - The basic and diluted earnings per share for Q1 2024 were both -0.075 RMB, an improvement from -0.085 RMB in Q1 2023[24] - The total cash and cash equivalents at the end of Q1 2024 were 19,021,898.11 RMB, compared to 9,415,253.24 RMB at the end of Q1 2023, indicating an increase of approximately 102%[28] - The company reported cash and cash equivalents of CNY 21,587,451.13, down from CNY 24,399,349.84[19] - The company's long-term investments in equity were CNY 720,674,631.93, up from CNY 710,409,931.49[20] - The company experienced a decrease in other comprehensive income, with a net amount of -145,687.31 RMB in Q1 2024, compared to 274,245.79 RMB in Q1 2023[24]

宁夏中科生物科技股份有限公司 2023 年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-3 | | 公司财务报表 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并股东权益变动表 | 9-10 | | — | 母公司股东权益变动表 | 11-12 | | — | 财务报表附注 | 13-110 | | 信永中和会计师事务所 北京市东城区朝阳门北大街 联系电话: +86 (010) 6554 2288 | | | --- | --- | | 8 号富华大厦 A 座 9 层 | telephone: +86 (010) 6554 2288 | | 9/F, Block A, Fu Hua Mansion, No.8, Chaoyangmen Beidajie, ShineWing | | | Dongcheng District, ...

明 1-4 关于对宁夏中科生物科技股份有限公司 2023 年度财务报表 出具无法表示意见审计报告的 专项说明 索引 页码 专项说 关于对宁夏中科生物科技股份有限公司 2023 年度财务报表出具无法表示意见审计报告的专项说明 XYZH/2024YCMC01F0005 宁夏中科生物科技股份有限公司 宁夏中科生物科技股份有限公司全体股东： 我们按照中国注册会计师审计准则审计了宁夏中科生物科技股份有限公司(以下简 称宁科生物公司)2023 年度财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债 表、2023 度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益 变动表以及财务报表附注，并于 2024 年 4 月 25 日出具了 XYZH/2024YCMC01B0116 号无 法表示意见的审计报告。 根据中国证券监督管理委员会《公开发行证券的公司信息披露编报规则第 14 号－ 非标准审计意见及其涉及事项的处理》、《监管规则适用指引—审计类第 1 号》以及上海 证券交易所的相关要求，我们对出具上述无法表示审计意见说明如下： 一、 发表无法表示意见的理由和依据 （一）合并报表的整体重要性 ...

二、董事会对独立董事独立性情况的评估意见 宁夏中科生物科技股份有限公司董事会 关于独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，宁夏 中科生物科技股份有限公司（以下简称：公司）董事会就公司在任独立董事的 独立性情况进行评估并出具如下专项意见： 一、独立董事独立性自查情况 公司现有独立董事 4 名，分别为岳修峰先生、娄亦捷先生、申屠宝卿女士、 王新灵先生。根据《上市公司独立董事管理办法》第六条的规定，公司独立董 事对自身的独立性情况进行了自查，并将自查情况提交了董事会。自查结果显 示，公司独立董事均符合《上市公司独立董事管理办法》独立性要求，不存在 直接或者间接利害关系，或者其他可能影响其进行独立客观判断关系的情形， 能够独立履行职责，不受公司及其主要股东、实际控制人等单位或者个人的影 响。 董 事 会 二〇二四年四月二十五日 经核查独立董事岳修峰先生、娄亦捷先生、申屠宝卿女士、王新灵先生的 任职经历及个人签署的相关自查文件，确认各位独立董事在报告期内未在公司 担任除独立董事以外的任何职务，亦 ...

公司主要采取现金分红的利润分配政策，即公司当年实现的可分配利润为正 值且累计未分配利润为正值；按要求足额预留法定公积金及任意公积金；审计机 构对公司当年财务报告出具标准无保留意见的审计报告，公司应当进行现金分 红。 宁夏中科生物科技股份有限公司 未来三年（2024-2026 年）股东分红回报规划 一、制定本规划考虑的因素 宁夏中科生物科技股份有限公司（以下简称：公司）着眼于长远和可持续发 展，在综合考虑公司盈利能力、经营发展规划、股东回报以及外部融资环境等因 素的基础上，充分考虑公司未来三年盈利能力、现金流量状况、项目投资需求、 银行信贷环境等情况，建立对投资者科学、持续、稳定的分红回报机制，保证公 司利润分配政策的持续性和稳定性。 二、制定本规划的原则 本规划的制定以符合相关法律、法规、《公司章程》及中国证券监督管理委 员会关于利润分配的规定为原则，兼顾公司持续发展需要和投资者合理回报需 求，实行持续、稳定的利润分配政策。 三、公司未来三年（2024-2026 年）股东分红回报规划 （一）利润分配形式 公司采取现金、股票或者现金股票相结合的方式分配利润。在公司盈利、现 金流量满足公司正常经营和长期发展的前提 ...

宁夏中科生物科技股份有限公司 独立董事 2023 年度述职报告 作为宁夏中科生物科技股份有限公司（以下简称：公司）的独立董事，本人 严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事规则》等相关法律、法规及《公司章程》等规章制度的规定和要求，认真、勤 勉、忠实履行独立董事职责，充分发挥了独立董事作用。2023 年积极参加公司股 东大会、董事会及专门委员会会议，对公司董事会审议的重大事项发表了公正、 客观的独立意见，为公司的长远发展出谋划策，对董事会的正确决策、规范运作 以及公司发展都起到了积极作用。同时，发挥各自的专业优势，积极关注和参与 研究公司发展，充分发挥独立董事的独立作用，有效地维护了公司、全体股东尤 其是中小股东的合法权益。现将 2023 年度履职情况报告如下： 一、独立董事基本情况 申屠宝卿：女，1965 年出生，博士学历，教授。曾任浙江大学助教、讲师、 副教授，浙江众成包装材料股份有限公司独立董事。现任浙江大学教授、博士生 导师，浙江福莱新材料股份有限公司独立董事，浙江仙通橡塑股份有限公司独立 董事，公司独立董事。2010 年获得独立董事资格证书。 作为公司独立董事本人 ...